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Abstract
Background: People living with HIV/AIDS (PLWH) have an excess risk for head
and neck squamous cell carcinoma (HNSCC) compared to the general U.S. population, but little is known about HIV-specific risk factors associated with the incidence
and outcomes HNSCC. We aim to identify clinical and HIV-specific risk factors
associated with oropharyngeal and non-oropharyngeal HNSCC incidence and outcomes separately.
Methods: We constructed a retrospective cohort study of 45,052 PLWH aged 18 or
above from the national Veteran Affairs (VA) Corporate Data from 1999 to 2015. We
extracted demographic data and risk factor information, including history of alcohol
abuse, smoking, CD4 count (cells/μl), and percent of follow-up time with undetectable HIV viral load as time-updated variables. We calculated the age-standardized
incidence rates of oropharyngeal and non-oropharyngeal HNSCC and estimated adjusted hazard ratios (HR). We also examined overall survival using Kaplan–Meier
curves and adjusted HR.
Results: The standardized incidence rate of oropharyngeal and non-oropharyngeal
HNSCC in this veteran cohort of PLWH is 23.0 (95% confidence intervals (CIs):
17.1-28.9) and 55.4 (95% CI: 46.5-64.3) per 100,000 person-years, respectively.
Nadir CD4 count ≤200 was associated with an increased risk of non-oropharyngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30 vs >200). Five-year overall survival of
OPSCC (37.0%) was significantly lower than non-oropharyngeal HNSCC (49.1%).
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Conclusions: PLWH who receive care in the VA had higher age-adjusted HNSCC
incidence rates than reported in the general population, suggesting that HIV and immunosuppression play a role. Additional studies should be conducted to study the
interaction between HPV and HIV.
KEYWORDS
head and neck cancer, HIV, incidence, survival
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IN TRO D U C T IO N

In the United States, approximately, 1.1 million people are
living with HIV.1 The total number of newly diagnosed HIV
cases has remained stable between 2012 and 2016, with
about 38,000 new cases a year.1 Since the introduction of
effective combination antiretroviral therapy (ART), the life
expectancy of people living with HIV/AIDS (PLWH) has
been approaching that of the non-HIV population.2 Thus,
there is a concern of an increasing rate of non-AIDS-defining cancers, including head and neck cancers, whose incidence sharply increases with aging in both HIV-infected and
non-infected populations. PLWH have a higher incidence of
both virus-related and tobacco/alcohol-related cancers due
to a higher prevalence of HIV-induced inflammation, immunodeficiency, and tobacco use among PLWH compared
with the non-HIV population.3,4 Indeed, as many as 20% of
deaths among people living with HIV/AIDS is due to invasive non-AIDS-defining cancers.
Squamous cell carcinoma of the head and neck region
(HNSCC) includes the oral cavity, oropharynx, hypopharynx, and larynx. Since HNSCC is strongly associated with
tobacco use, the incidence for most of the sites has been decreasing.5,6 In stark contrast, the incidence of squamous cell
carcinoma of the oropharynx (OPSCC) is rising at an epidemic rate due to its relationship with the human papillomavirus (HPV);6 OPSCC has now overtaken cervical cancer as
the most common HPV-positive malignancy.7 Prior studies
have shown that PLWH have an excess risk of HNSCC compared to the non-HIV population, which could be due to a
higher prevalence of tobacco and alcohol use. However, the
elevated risk of lung cancer––another smoking-related cancer––is not entirely explained by smoking, suggesting HIVrelated immune suppression and chronic inflammation are
also likely contributors.8 The drivers of increased HNSCC
risk in PLWH patients are entirely unclear in the context of
HPV-positive OPSCC. Since both HPV-negative and HPVpositive head and neck cancers have high levels of immune
infiltrate,9 suggesting the immune system plays an essential
role in HNSCC development and survival.
Given the heterogeneity in the risk of HNSCC in people
living with HIV and the importance of the immune system,

we aimed to identify risk factors associated with oropharyngeal and non-oropharyngeal HNSCC in a large retrospective
cohort study of PLWH identified in the U.S. national Veterans
Health Administration (VHA) system. We also examined factors associated with survival among veterans living with HIV
with HNSCC.

2

|

2.1

M ETHODS

|

Study population and design

We performed a retrospective cohort study using individual-level patient data from the national VA Corporate Data
Warehouse (CDW) and the VA Central Cancer Registry
(CCR) from 1999 to 2015. Detailed information about cohort
construction and inclusion has been previously described.10
Briefly, the cohort of PLWH included patients aged 18 or
above who fulfilled two out of the three following criteria:
(1) patients with at least one positive HIV antibody test by
Elisa or Western Blot; tested for HIV viral load (any +/-/
indeterminate); or tested for CD4+ count; (2) patients with
at least one prescription in inpatient or outpatient pharmacy records for HIV antiretroviral therapy (ART); and (3)
any inpatient or outpatient encounter with an International
Classification of Diseases, Ninth Revision (ICD-9) (042 or
V08) or ICD-10 code (B20 & Z21) for HIV. We used the
earliest date of the HIV diagnostic criteria as the index date
of follow-up unless it was before 10/01/1999 (inception date
of CDW data), in which case we assigned 10/01/1999 as the
HIV patient's index date.

2.2
2.2.1

|

Variable specification

|

Outcomes

We are interested in two outcomes, first is HNSCC among
the whole cohort and second survival among the HNSCC
cohort (Figure 1). For the first incidence outcome (yellow
box in Figure 1), we used a hierarchical approach to define
the occurrence of OPSCC or non-oropharyngeal HNSCC in
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FIGURE 1

Schematic for the incidence (yellow box) and survival (blue box) study design

the cohort. First, we identified all head and neck squamous
cancer cases in the VA CCR based on primary site of OPSCC
and non-oropharyngeal HNSCC defined as oral cavity, hypopharynx, and larynx cancer. We then identified patients
with any ICD-9 or ICD-10 code for HNSCC (Table S1). We
examined the discordance of cancer diagnosis between the
VA CCR and ICD-9/ICD-10 with a manual review of the
electronic medical record (EMR) to determine their true cancer status. This hierarchical approach ensured a high validity
of all the captured cancer cases. We then excluded all prevalent cancer cases that were diagnosed any time before the
HIV index date through to 90 days after the index date.
For the second outcome of mortality (blue box in Figure
1), all-cause mortality was identified from the VA Vital
Status file, which combines information from Medicare, VA,
Social Security, and VA compensation and pension benefits
to determine the date of death with a sensitivity of 98.3%
and specificity of 99.8% when compared with the National
Death Index.11 During follow-up, only one female developed
non-oropharyngeal HNSCC, and none developed OPSCC.
Thus, we excluded female patients from this study.

2.2.2

|

Covariates

We used a previously reported method to abstract and to classify covariates.12 Briefly, we extracted demographic data and
risk factor information using ICD codes and pharmacy and
laboratory data from the CDW, including age at index date,

sex, race/ethnicity (White, Black, and other/unknown), history of alcohol abuse (yes, no), and smoking (ever or missing, never), and gastroesophageal reflux disease (GERD;
ever, never). We defined baseline body mass index (BMI) by
using the closest height and weight values in the 2 years before or after the index date. HIV-specific variables included
were nadir CD4 count (cells/μL) and percent of follow-up
time with undetectable HIV viral load, both as time-updated
variables throughout the study period.

2.3

|

Statistical analysis

2.3.1 | Incidence and risk factors for
HNSCCs in veterans living with HIV
We compared baseline characteristics between patients with
OPSCC, non-oropharyngeal HNSCC, and patients without an
HNSCC diagnosis (i.e., controls) using a student's t-test for
continuous variables and chi-square tests for categorical variables. Therefore, follow-up time at risk was calculated from
90 days after the index date––the possible earliest start date
of follow-up was 1/1/2000––to the development of HNSCC,
death, or 12/31/2016, whichever was earlier. We calculated
incidence rates age-standardized to the 2000 U.S. population
for HNSCC in the PLWH per 100,000 person-years (PY) in
oropharyngeal and non-oropharyngeal HNSCC separately.
We then estimated adjusted hazard ratios (HR) and 95% confidence intervals (CIs) for the risks of non-oropharyngeal
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Descriptive statistics of PLWH who received healthcare at VA from 1999 to 2015 by head and neck cancer diagnosis.
No cancer

Oropharyngeal

Non-oropharyngeal

n = 43,663

n = 119

n = 270

n (%)

n (%)

n (%)

p-value

Age at index date
<40
40-59
60 and above

9889 (22.7)

14 (11.8)

28 (10.4)

28350 (64.9)

91 (76.5)

194 (71.9)

5424 (12.4)

14 (11.8)

48 (17.8)

22847 (52.3)

68 (57.1)

131 (48.5)

<0.001

Race
Black
Other/Unknown
White

4257 (9.8)

6 (5.0)

18 (6.7)

16559 (37.9)

45 (37.8)

121 (44.8)

35079 (80.3)

104 (87.4)

248 (91.9)

8584 (19.7)

15 (12.6)

22 (8.1)

0.041

Smoking
Ever or unknown smoker
Lifelong non-smoker

<0.001

Alcohol abuse
No

24605 (56.4)

54 (45.4)

157 (58.1)

Yes

19058 (43.6)

65 (54.6)

113 (41.9)

No

24957 (57.2)

55 (46.2)

161 (59.6)

Yes

18706 (42.8)

64 (53.8)

109 (40.4)

0.046

Substance abuse
0.039

Baseline BMI
1543 (3.5)

3 (2.5)

7 (2.6)

<25

Missing

21063 (48.2)

77 (64.7)

157 (58.2)

25-29.9

14559 (33.3)

26 (21.8)

84 (31.1)

6498 (14.9)

13 (10.9)

22 (8.1)

No

33277 (76.2)

78 (65.6)

166 (61.5)

Yes

10386 (23.8)

41 (34.5)

104 (38.5)

>30

<0.001

GERD (ever)
<0.001

HCV (ever)
No

33882 (77.6)

80 (67.2)

198 (73.3)

Yes

9781 (22.4)

39 (32.8)

72 (26.7)

1409 (3.2)

2 (1.7)

10 (3.7)

0.006

Nadir CD4 (at cancer/censor)
Missing
≤200

21159 (48.5)

63 (52.9)

152 (56.3)

>200

21095 (48.3)

54 (45.4)

108 (40.0)

1175 (2.7)

1 (0.8)

3 (1.1)

0.061

Viral load percentage of time
undetectable (at cancer/censor)
Missing
<40%

11081 (25.4)

34 (28.6)

98 (36.3)

40%-80%

11933 (27.3)

35 (29.4)

66 (24.4)

>80%

19474 (44.6)

49 (41.2)

103 (38.2)

0.002

Year first HIV
Before 1996
1996-2000

8582 (19.7)

41 (34.5)

80 (29.6)

10161 (23.3)

38 (31.9)

93 (34.4)

2001-2005

9240 (21.2)

20 (16.8)

63 (23.3)

2006-2016

15680 (35.9)

20 (16.8)

34 (12.6)

Abbreviations: BMI, Body Mass Index; GERD, Gastroesophageal reflux disease; HCV, Hepatitis C virus; PLWH, People living with HIV.

<0.001
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HNSCC and OPSCC using Cox proportional hazards regression models from index date plus 90 days to cancer or
censor. We used forward selection to include covariates that
changed estimates more than 10% or deemed clinically relevant. We adjusted for age at index, race, smoking, baseline
BMI, GERD, viral load percentage of time undetectable
(time-dependent), nadir CD4 (time-dependent), and year first
HIV diagnosis.

2.3.2 | Risk factors for mortality among
People Living with HIV with HNSCC
We also examined survival using Kaplan–Meier curves for
both oropharyngeal and non-oropharyngeal HNSCC as well
as risk factors for mortality among PWLH with these cancers
using Cox proportional hazards regression analysis the cancer date to death or censor. We examined the same potential
confounder variables as examined in our Cox models for cancer incidence, as described above.

|

2.3.3

HPV status exploratory analysis

To estimate the effect of HPV in OPSCC, we abstracted
HPV status from medical records for all OPSCCs diagnosed after 2010 (HPV testing was not recommended
2010).13 Cases were classified as HPV-positive if the
case was positive for either p16 immunohistochemistry or
HPV in situ hybridization and as HPV-negative if one test
was negative and the other was unknown or untested. We
compared univariate demographics and survival between
HPV-positive, HPV-negative, and unknown HPV status at
OPSCC diagnosis using statistics described above. We did
not perform Cox regression given limited power due to reduced sample size.
Analyses were performed using SAS version SAS
Enterprise Guide Version 7.15 (SAS Institute, Cary, NC).
Statistical significance was determined at α=0.05, and
P-values for statistical significance were two-sided.

3
3.1

|

R ES U LTS

|

Descriptive statistics

We included data from 44,052 veterans living with HIV/
AIDS using VA healthcare. (Table 1). As expected, in our
cohort, patients with OPSCC were younger than patients
with non-oropharyngeal HNSCC (11.8% vs 17.8% older
than 60 years at HIV index date, respectively) and controls
(12.4% older than 60 years at HIV index date). OPSCC cases
were more likely to be lifelong non-smokers compared with

non-oropharyngeal HNSCC cases (12.6% vs 8.1% nonsmoker, respectively) and controls (19.7%). OPSCC cases
were more likely to have a history of alcohol abuse (54.6%
in OPSCC vs 41.9% non-oropharyngeal HNSCC) and substance abuse (53.8% in OPSCC vs 40.4% non-oropharyngeal
HNSCC) compared with both noncancer subjects and nonoropharyngeal HNSCC cases.

3.2 | Incidence of OPSCC and nonoropharyngeal HNSCC in PLWH
Of the 44,052 PLWH in our nationwide VA cohort, there
were 119 cases of incident OPSCC and 270 cases of non-oropharyngeal HNSCC. The age-standardized rate of OPSCC
was 23.0 (95% CI: 17.1-28.9) per 100,000 PY. The agestandardized rate of non-oropharyngeal HNSCC was higher
at 55.4 (95% CI: 46.5-64.3) per 100,000 PY.
In the adjusted Cox regression (Table 2), age greater
than 60 years was associated with increased risk of both
OPSCC (HR: 3.35; 95% CI: 1.56-7.18) and non-oropharyngeal HNSCC (HR: 5.80; 95% CI: 3.58-9.39) compared
with age <40 years in PLWH. Ever smoking was only
associated with risk of developing non-oropharyngeal
HNSCC but not OPSCC (HR: 2.38; 95% CI: 1.53-3.71 vs
HR: 1.28; 95% CI: 0.73-2.23, respectively). Nadir CD4
≤200 was associated with an increased risk of non-oropharyngeal HNSCC (HR: 1.78; 95% CI: 1.31-2.30). GERD
was also associated with the risk of non-oropharyngeal
HNSCC (HR: 1.46; 95% CI: 1.14-1.87). Year of HIV diagnosis was significantly associated with decreased risk
of both OPSCC (HR: 0.49; 95% CI: 0.28-0.85 for 20012005 vs prior to 1999) and non-oropharyngeal HNSCC
(HR: 0.56; 95% CI: 0.36-0.88 for 2006-2016 vs prior to
1999).

3.3

|

Survival for HNSCC in PLWH patients

Overall survival (OS) for OPSCC (5-year OS: 37.0%; Figure
2) was significantly lower than that of non-oropharyngeal
HNSCC (5-year OS: 49.1%; log-rank p-value=0.005). We
further categorized non-oropharyngeal HNSCC into hypopharynx (n = 24), larynx (n = 120), nasopharynx (n = 11)
and oral cavity (n = 115). Five-year OPSCC OS was lower
than survival for both larynx (45.6%) and oral cavity cancer
(65.4%; Figure S1A). These trends also continued when stratified by smoking, where smokers with OPSCC had a worse
survival than smokers with non-oropharyngeal HNSCC
(Figure S1B). The 5-year OS in stage III–IV was lower than
stage I-II in both OPSCC (I–II: 40.4%, III–IV: 30.9%, Figure
S1C) and non-oropharyngeal HNSCC (I–II: 66.2%, III–IV:
22.67%, Figure S1D).
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T A B L E 2 Mutually adjusted hazard ratios for the risk of oropharyngeal and non-oropharyngeal cancer in PLWH receiving healthcare at VA
from 1999 to 2015.
Oropharyngeal
HR (95% CI)

Non-oropharyngeal
p-value

HR (95% CI)

p-value

Age at index
<40

1.00

1.00

40-59

2.17 (1.23, 3.84)

0.008

2.35 (1.57, 3.50)

<0.001

60 and above

3.35 (1.56, 7.18)

0.002

5.80 (3.58, 9.39)

<0.001

Race
White

1.000

1.00

Black

1.00 (0.68, 1.47)

0.993

0.77 (0.59, 0.99)

0.040

Other/Unknown

0.65 (0.28, 1.54)

0.329

0.75 (0.46, 1.24)

0.264

0.386

2.38 (1.53, 3.71)

Smoking
Lifelong non-smoker

1.00

Ever or unknown smoker

1.28 (0.73, 2.23)

1.00
<0.001

Alcohol
No

1.00

Yes

1.81 (1.23, 2.66)

1.00
0.003

1.16 (0.90, 1.51)

0.253

Baseline BMI
<25

1.00

1.00

25-29.9

0.48 (0.31, 0.76)

0.001

0.79 (0.60, 1.03)

0.081

>30

0.63 (0.35, 1.14)

0.130

0.56 (0.35, 0.87)

0.010

Missing

0.50 (0.16, 1.62)

0.250

0.52 (0.24, 1.12)

0.092

GERD
No

--

Yes

--

1.00
--

1.46 (1.14, 1.87)

0.003

Viral load percentage of time undetectable
(time-dependent)
<40%

1.00

40%-80%

1.19 (0.73, 1.95)

0.486

0.78 (0.56, 1.09)

1.00
0.144

>80%

1.29 (0.81, 2.07)

0.283

0.85 (0.63, 1.15)

0.288

Missing

1.50 (0.18, 12.28)

0.708

0.92 (0.27, 3.16)

0.895

Nadir CD4 (time-dependent)
>200

1.00

≤200

1.39 (0.95, 2.02)

0.088

1.78 (1.31, 2.30)

1.00
<0.001

Missing

0.38 (0.51, 2.28)

0.112

1.14 (0.56, 2.30)

0.721

Year first HIV
Before 1996

1.00

1.00

1996-2000

0.82 (0.52, 1.27)

0.366

1.02 (0.76, 1.38)

0.880

2001-2005

0.49 (0.28, 0.85)

0.011

0.83 (0.59, 1.17)

0.282

2006-2016

0.69 (0.38, 1.26)

0.223

0.56 (0.36, 0.88)

0.011

Abbreviations: BMI, Body Mass Index; GERD, Gastroesophageal reflux disease; PLWH, People living with HIV.

In multivariable Cox analysis for survival, ever smoking
was significantly associated with increased risk of death, and
BMI was associated with a decreased risk of death among both
OPSCC and non-oropharyngeal HNSCC patients (Table 3).

Although not significant, nadir CD4 count was also associated
with OPSCC survival, where cases with nadir CD4 count less
than or equal to 200 had 2.00 times the hazard of death (95% CI:
0.94-4.27) compared to those with nadir CD4 greater than 200.
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FIGURE 2

Kaplan–Meier curve for survival after between
oropharyngeal and non-oropharyngeal cancer

3.4 | HPV impact on OPSCC survival
in PLWH
In our sensitivity analysis examining HPV in OPSCC, we
found of the 62 cases diagnosed since 2010, 56.4% (n = 35)
were tested for HPV. Of these, 88.6% (n = 31) were HPVpositive and 11.4% (n = 4) were HPV-negative. Older individuals, smokers, and those whose cancer was first diagnosed
before 2013 were less likely to be tested (Table S2). In a
Kaplan–Meier curve (Figure 3), HPV-negative and unknown
cases had worse OS (5-year OS: 18.3%) than HPV-positive
cases (5-year OS: 59.4%).

4

|

D IS C U S S ION

In this large retrospective cohort study of veterans living with
HIV using the nationwide VA healthcare system, we found
that the age-standardized rate of non-oropharyngeal HNSCC
is higher compared with age-standardized rates of OPSCC.
The HIV-specific variable associated with non-oropharyngeal HNSCC was nadir CD4 count, which was associated
with an increased risk of cancer. We are also the first study
to demonstrate lower survival in OPSCC compared with laryngeal and oral cavity cancer in both PLWH and veterans.
This trend is consistent when stratified by stage. Upon further
inspection, we found evidence that, although HPV-positive
OPSCC has better survival than non-HPV OPSCC, survival
is still lower in PLWH then the non-HIV population.
The incidence of HNSCC is higher in PWLH compared
with the general SEER population,14,15 which is paralleled in
our study where we see a higher incidence of both OPSCC
and non-oropharyngeal HNSCC. PLWH tend to have
more risk factors for cancer, such as risky sexual behavior,

MAZUL et al.

smoking, and immunosuppression.16 The age-standardized
incidence of OPSCC and non-oropharyngeal HNSCC in our
study is higher than previously reported in North American
AIDS Cohort Collaboration on Research and Design (NAACCORD) consortium (40 per 100,000 person-years and
10.7 per 100,000 person-years, respectively).3 The NA
ACCORD consortium has pooled data from 17 prospective
studies, including data from the VHA. However, our cohort
was developed separately from the Veterans Aging Cohort
(VACS) using a separate methodology. Additionally, male
veterans who have a higher prevalence of cancer risk factors
such as smoking and alcohol use thus represents a different
target population from NA ACCORD.17
Overall, we see results similar to those observed in the
NA ACCORD consortium. Age appears to one of the most
significant risk factors for HNSCC among PLWH, which
is relevant given the aging PLWH population. We found no
association between HIV-related factors and OPSCC, supporting previous research that immunosuppression is more
relevant for non-HPV associated HNSCC than HPV-positive
cancer.18,19 The increased but nonsignificant association of
CD4 count may be due to the impact of CD4 early in HPVpositive cancer by affecting HPV persistence. 20,21
On the contrary, for non-HPV-positive cancer, CD4 count
would reflect reduced immune surveillance for malignant
cells in the development of HNSCC.22 Alternatively, there
is evidence that CD4 count decline could be due to undiagnosed cancer, rather than causing cancer. However, this has
mainly been observed in lymphomas, and, in our study, the
nadir CD4 count associated with cancer could be many years
before the incident cancer diagnosis.
The relationship between GERD and non-oropharyngeal
HNSCC is mixed with many earlier studies suggesting an
association with hypopharynx or larynx cancer, but recent
studies have not supported these findings.23-26 Our study is
the first study of PLWH to examine GERD, in which we
observed an association of GERD with non-oropharyngeal
HNSCC. However, this association could be due to reverse
causality, where the symptoms of laryngeal cancer mimic
those of GERD. Thus, both are more likely diagnosed. Future
studies may determine if this increased risk is simply due to
detection bias.
This is the first large cohort study of HNSCC among
PLWH that includes survival and stage. Survival in this cohort is lower than the SEER population for both OPSCC and
non-oropharyngeal HNSCC. The lower survival compared
to the non-veteran and non-HIV population could be due to
the increased prevalence of smoking and medical conditions
in the VA in addition to decreased immune response due to
HIV. Low CD4 count is associated with increased risk of
death in OPSCC, but not non-oropharyngeal HNSCC. HPVpositive OPSCC tumors tend to have more immune infiltrated and have higher levels of T cells. We also found the
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Mutually adjusted hazard ratios for risk of mortality among PLWH in the VA after oropharyngeal and non-oropharyngeal cancer
Oropharynx
(N event =80)

Non-oropharynx
(N event =147)

N (%)

HR (95% CI)

p-value

N (%)

<40

14 (11.8)

1.00

40-59

91 (76.5)

60 and above

HR (95% CI)

28 (10.4)

1.00

1.04 (0.40, 2.69)

0.939

194 (71.9)

5.91 (1.85, 18.87)

0.003

14 (1.8)

2.41 (0.75, 7.80)

0.141

48 (17.8)

9.04 (2.68, 30.45)

<0.001

Non-smoker

104 (87.4)

1.00

248 (91.9)

1.00

Ever or unknown smoker

15 (12.6)

2.96 (1.25, 6.99)

22 (8.1)

3.31 (1.35, 8.12)

<25

77 (66.4)

1.00

157 (59.5)

1.00

25-29.9

26 (22.4)

0.80 (0.43, 1.49)

0.489

85 (32.2)

0.51 (0.34, 0.76)

0.001

>30

13 (11.2)

0.26 (0.09, 0.74)

0.012

22 (8.3)

0.86 (0.41, 1.81)

0.690

<40%

28 (23.7)

1.00

61 (22.8)

1.00

40%-80%

39 (33.1)

1.31 (0.73, 2.34)

0.369

98 (36.7)

0.89 (0.58, 1.36)

0.588

>80%

51 (43.2)

0.71 (0.38, 1.32)

0.284

108 (40.4)

0.78 (0.51, 1.19)

0.244

>200

106 (89.1)

1.00

195 (73.0)

1.00

≤200

13 (10.9)

2.00 (0.94, 4.27)

72 (27.0)

1.11 (0.75, 1.64)

I-II

22 (18.5)

1.00

119 (44.1)

1.00

III-IV

86 (72.3)

1.52 (0.86, 2.71)

0.153

94 (34.8)

2.63 (1.79, 3.88)

<0.001

Unknown

11 (9.2)

0.70 (0.22, 2.26)

0.549

57 (21.1)

1.55 (0.97, 2.48)

0.069

p-value

Age at index date

Smoking
0.013

0.009

Baseline BMI

Viral load percentage
of time undetectable
(time-dependent*)

*

Nadir CD4 (time-dependent )
0.072

0.597

Stage

Abbreviation: BMI, body mass index.
*N (%) is at cancer/censor

survival of OPSCC to be much lower than the survival of
non-oropharyngeal HNSCC, even given the lower prevalence
of suggesting there is an interaction between HIV and HPV
in OPSCC. Coupled with increased risk among PLWH, immunity may play a more crucial role in HPV-positive cancers
than in non-HPV-positive HNSCCs.
In a subset analysis, we found that among the cases tested
for HPV, the majority are HPV-positive, which is similar to
previous studies of HPV status in OPSCC in the VA.27 We also
found that although HPV-positive OPSCC cases have better
survival than HPV-negative OPSCC, they still have lower
survival than the non-HIV population. Two-year survival for
HPV-positive OPSCC for all stages has been reported to be as
high at 90% in the non-HIV non-Veteran population.28,29 This
difference in survival signifies that host immune likely plays
an essential role in the increased survival of HPV-positive
OPSCC. Smoking is also a likely driver of poor outcomes,
particularly in the Veteran population with high rates of

tobacco use. Smoking worsens prognosis in HPV-positive
OPSCC, increasing the risk of death by 1% for every one
pack-year of smoking.30-32 However, to date, few studies have
considered the interaction between HIV and HPV in OPSCC,
and one previous study of OPSCC among PWLH found no
difference in survival by HPV status,33 This discordance justifies additional examination of the interaction between HPV
and HIV in OPSCC specifically.
Given both the increased risk of HNSCC and higher rates
of death from HNSCC among PLWH, there is a strong case
for dysfunctional immunity as a driver of poor HNSCC outcomes in this population. Both HPV- and tobacco-associated HNSCCs have an immunosuppressive tumor immune
microenvironment.34,35 Specifically, HPV-positive OPSCC
inherently represents a failure of host immunity, allowing
HPV infection, persistence, and progression to carcinoma go
unchecked. In the non-HIV population, improved survival
may be in part due to enhanced immune response induced by
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to better survival and the incidence of HPV-positive OPSCC
increases, the interaction between the HPV and HIV becomes increasingly relevant, especially since HPV-positive
OPSCCs among PLWH in our cohort do not have the generally favorable survival seen in the non-HIV population. This
growing concern needs a dedicated effort and resources as
well as additional studies to study the interaction between
HPV, tobacco, and HIV in OPSCC.

FIGURE 3

Survival among PLWH in the VA with
oropharyngeal cancer by p16/HPV status

radiation therapy.9,36 ART-associated immune reconstitution
fails to completely restore immune populations required for
successful control of cancer after radiation therapy.
Our study has several limitations. First, it was a historical cohort and may be subject to unmeasured confounders
such as sexual behavior and misclassification of covariates. However, we attempted to adjust for this through
ICD-9 codes identifying individuals with a history of both
alcohol and drug use. Although we were able to abstract
HPV data on some of the OPSCC cases, we lacked information about the tumor HPV status of for most of the
OPSCC cases, since only about half the cases after 2010
were tested for HPV. Finally, this study was limited to
male veterans. Veterans are a select group that has lower
socioeconomic status, more medical conditions, which
would limit the generalizability to the other populations
of PWLH.37
Our study has multiple notable strengths. The VHA is
the most extensive integrated healthcare system and provider
of comprehensive HIV care in the United States. By taking
advantage of the comprehensive fully automated nationwide
VA clinical, laboratory, and administrative databases (CDW
and CCR) along with manual electronic medical records
abstractions, we constructed a large cohort of PLWH with
extensive follow-up and individual-level data. Additionally,
this is the largest study published to date evaluating HNSCC
survival among PLWH.
In summary, HNSCC is more common among PLWH
than in the general U.S. population. Certain HIV-specific
variables such as CD4 count are associated with increased
risk suggesting that HIV, and thus, the host immune system,
in addition to increased prevalence of head and neck risk factors such as smoking and HPV, increases the risk of HNSCC.
As the prevalence of both HIV rises in the United States due

AUTHOR CONTRIBUTIONS
EC, JK, and DLW conceived and designed this study. STA,
KR, CH, and SR collected and curated the data. CH performed the data analysis. ALM, CH, KR, DLM, PR, and EC
were involved with the interpretation. ALM drafted the article. ALM, CH, KR, DLW, KR, SR, VS, STA, PR, AGS, and
EC provided critical revision. All authors approved of the
version to be published.
DATA AVAILABILIT Y STATEMENT
Data subject to third party restrictions. The data that support
the findings of this study are available from Veteran Affairs.
Restrictions apply to the availability of these data, which
were used under license for this study. Data are available
from the authors with the permission of Veteran Affairs.
ORCID
Angela L. Mazul
R E F E R E NC E S

https://orcid.org/0000-0002-1249-4613

1. Centers for Disease Control and Prevention. Diagnoses of HIV
Infection in the United States and Dependent Areas, 2017. HIV
Surveillance Report, 2017. vol. 29.
2. Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases
in life expectancy among treated HIV-positive individuals in the
United States and Canada. PLoS One. 2013;8:e81355.
3. Hernandez-Ramirez RU, Shiels MS, Dubrow R, Engels EA.
Cancer risk in HIV-infected people in the USA from 1996 to
2012: a population-based, registry-linkage study. Lancet HIV.
2017;4:e495-e504.
4. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks,
and cessation strategies. Current HIV/AIDS Rep. 2012;9:223-230.
5. Mourad M, Jetmore T, Jategaonkar AA, Moubayed S, Moshier E,
Urken ML. Epidemiological trends of head and neck cancer in the
United States: A SEER Population Study. J Oral Maxillofac Surg.
2017;75:2562-2572.
6. Rettig EM, D'Souza G. Epidemiology of head and neck cancer.
Surg Oncol Clin N Am. 2015;24:379-396.
7. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer
J Clin. 2020;70:7-30.
8. Sigel K, Makinson A, Thaler J. Lung cancer in persons with HIV.
Current Opinion in HIV and AIDS. 2017;12:31-38.
9. Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015;33:3293-3304.
10. Kramer JR, Hartman C, White DL, et al. Validation of HIVinfected cohort identification using automated clinical data in the
Department of Veterans Affairs. HIV Medicine. 2019;20:567-570.

  

MAZUL et al.

11. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Affairs.
Popul Health Metr. 2006;4:2.
12. Thrift AP, Kramer JR, Hartman CM, et al. Risk and predictors of esophageal and stomach cancers in HIV-infected veterans: a matched cohort study. J Acquir Immune Defic Syndr.
2019;81:e65-e72.
13. Robinson M, Sloan P, Shaw R. Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus
testing. Oral Oncol. 2010;46:492-496.
14. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk
among people with AIDS in the United States 1980–2002. Aids.
2006;20:1645-1654.
15. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of
cancer among HIV-infected persons compared with the general
population in the United States, 1992–2003. Ann Intern Med.
2008;148:728-736.
16. Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the
Swiss HIV Cohort Study: associations with immunodeficiency,
smoking, and highly active antiretroviral therapy. J Natl Cancer
Inst. 2005;97:425-432.
17. Zullig LL, Sims KJ, McNeil R, et al. Cancer incidence among
patients of the U.S. Veterans Affairs Health Care System: 2010
Update. Military Med. 2017;182(7):e1883-e1891.
18. Beachler DC, Abraham AG, Silverberg MJ, et al. Incidence and
risk factors of HPV-related and HPV-unrelated Head and Neck
Squamous Cell Carcinoma in HIV-infected individuals. Oral
Oncol. 2014;50:1169-1176.
19. Engels EA, Madeleine MM. Invited commentary: biological and
clinical insights from epidemiologic research into HIV, HPV, and
anal cancer. Am J Epidemiol. 2013;178:885-887.
20. D'Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J
Cancer. 2007;121:143-150.
21. Beachler DC, Weber KM, Margolick JB, et al. Risk factors for oral
HPV infection among a high prevalence population of HIV-positive
and at-risk HIV-negative adults. Cancer Epidemiol Biomark Prev.
2012;21:122-133.
22. Buggert M, Nguyen S, McLane LM, et al. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during
health and HIV disease. PLoS Pathog. 2018;14:e1006973.
23. El-Serag HB, Hepworth EJ, Lee P, Sonnenberg A. Gastroesophageal
reflux disease is a risk factor for laryngeal and pharyngeal cancer.
Am J Gastroenterol. 2001;96:2013-2018.
24. Busch EL, Zevallos JP, Olshan AF. Gastroesophageal reflux disease and odds of head and neck squamous cell carcinoma in North
Carolina. Laryngoscope. 2016;126:1091-1096.
25. Anis MM, Razavi MM, Xiao X, Soliman AMS. Association of
gastroesophageal reflux disease and laryngeal cancer. World J
Otorhinolaryngol Head Neck Surg. 2018;4:278-281.
26. Francis DO, Maynard C, Weymuller EA, Reiber G, Merati AL,
Yueh B. Reevaluation of gastroesophageal reflux disease as

27.

28.

29.

30.

31.

32.

33.

34.
35.

36.

37.

|

9335

a risk factor for laryngeal cancer. Laryngoscope. 2011;121:
102-105.
Park J, McPike V, Kambhampati S, et al. Positivity rates in oropharyngeal and nonoropharyngeal head and neck cancer in the VA.
Fed Pract. 2018;35:S44-S47.
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and
survival of patients with oropharyngeal cancer. N Engl J Med.
2010;363:24-35.
Heiduschka G, Grah A, Oberndorfer F, et al. Improved survival in HPV/p16-positive oropharyngeal cancer patients treated
with postoperative radiotherapy. Strahlenther Onkol. 2015;191:
209-216.
Haigentz M, Suarez C, Strojan P, et al. Understanding interactions
of smoking on prognosis of HPV-associated oropharyngeal cancers. Advances in Therapy. 2018;35:255-260.
Sandulache VC, Wilde DC, Sturgis EM, Chiao EY, Sikora AG.
A hidden epidemic of "Intermediate Risk" oropharynx cancer.
Laryngoscope Investig Otolaryngol. 2019;4:617-623.
Kemnade JO, Elhalawani H, Castro P, et al. CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. Sci Rep. 2020;10:243.
DʼSouza G, Carey TE, William WN, et al. Epidemiology of head
and neck squamous cell cancer among HIV-infected patients. J
Acquir Immune Defic Syndr. 2014;65:603-610.
Whiteside TL. Head and neck carcinoma immunotherapy: facts
and hopes. Clin Cancer Res. 2018;24:6-13.
Tong CC, Kao J, Sikora AG. Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.
Immunol Res. 2012;54:266-274.
Liu C, Mann D, Sinha UK, Kokot NC. The molecular mechanisms
of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol
Head Neck Surg. 2018;47:59.
Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients
at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med.
2000;160:3252-3257.

SUPPORTING INFORMATION
Additional supporting information may be found online in
the Supporting Information section.

How to cite this article: Mazul AL, Hartman C,
Kramer J, et al. Incidence and survival for oropharynx
and non-oropharynx head and neck cancers among
veterans living with HIV. Cancer Med. 2020;9:9326–
9335. https://doi.org/10.1002/cam4.3539

